Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 98 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| IGM Biosciences Inc | IGMS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 7.70 | 08:04:33 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 7.70 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 7 | 98 | - | 3.81 - 17.70 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:03:59 | 31 | $ 7.48 | USD |
IGM Biosciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 452.66M | 58.79M | - | 2.13M | -246.42M | -4.19 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
IGM Biosciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IGMS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 9.37 | 9.37 | 6.70 | 7.47 | 314,131 | -1.67 | -17.82% |
| 1 Month | 8.79 | 10.85 | 6.70 | 8.46 | 224,711 | -1.09 | -12.40% |
| 3 Months | 9.77 | 17.70 | 6.70 | 11.70 | 269,722 | -2.07 | -21.19% |
| 6 Months | 4.47 | 17.70 | 3.81 | 9.07 | 303,828 | 3.23 | 72.26% |
| 1 Year | 11.35 | 17.70 | 3.81 | 8.99 | 296,274 | -3.65 | -32.16% |
| 3 Years | 61.00 | 99.44 | 3.81 | 23.42 | 326,333 | -53.30 | -87.38% |
| 5 Years | 18.31 | 127.11 | 3.81 | 32.15 | 270,517 | -10.61 | -57.95% |
IGM Biosciences Description
| IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies. |
